A Phase III Randomized Double-blind, 12 Week, Placebo Controlled Trial of Transdermal Selegiline in Borderline Personality Disorder (BPD) to Evaluate Efficacy and Safety

Trial Profile

A Phase III Randomized Double-blind, 12 Week, Placebo Controlled Trial of Transdermal Selegiline in Borderline Personality Disorder (BPD) to Evaluate Efficacy and Safety

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2015

At a glance

  • Drugs Selegiline (Primary)
  • Indications Borderline personality disorders
  • Focus Therapeutic Use
  • Sponsors Mood and Anxiety Research
  • Most Recent Events

    • 07 Oct 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 07 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top